Evidence map›Paper›PMID 41550985›Full record

ArticleBladder cancer (Amsterdam, Netherlands)

Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer.

Ernest Kaufmann, Stefanie Aeppli, Andres Affentranger, Nicolas Arnold, Winfried Arnold, Fabian Aschwanden, Panagiotis Balermpas, Jörg Beyer, Uwe Bieri, Joost Boormanns and 39 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bladder cancer (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

49 authors.

Ernest KaufmannDepartment of Urology, University Teaching and Research Hospital of the University of Lucerne, Switzerland.ORCID https://orcid.org/0009-0002-8250-4634
Stefanie AeppliDepartment of Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Andres AffentrangerDepartment of Urology, University Teaching and Research Hospital of the University of Lucerne, Switzerland.ORCID https://orcid.org/0000-0002-6685-2180
Nicolas ArnoldDepartment of Urology, Inselspital Bern, Berne, Switzerland.ORCID https://orcid.org/0009-0006-4122-8249
Winfried ArnoldDepartment of Radiation-Oncology, University Teaching and Research Hospital of the University of Lucerne, Lucerne, Switzerland.
Fabian AschwandenDepartment of Urology, University Teaching and Research Hospital of the University of Lucerne, Switzerland.
Panagiotis BalermpasDepartment of Radiation-Oncology, University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0001-5261-6446
Jörg BeyerDepartment of Oncology, Inselspital Bern, Berne, Switzerland.
Uwe BieriDepartment of Urology, Kantonsspital Baden, Baden, Switzerland.ORCID https://orcid.org/0000-0002-7339-1458
Joost BoormannsDepartment of Urology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.
Richard CathomasDepartment of Oncology, Kantonsspital Chur, Chur, Switzerland.
Berardino De BariDepartment of Radiation-Oncology, Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland.
Marco DresslerZentrum für Onkologie Luzern, Lucerne, Switzerland.
Daniel S EngelerDepartment of Urology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Andreas ErdmannDepartment of Oncology, Kantonsspital Baden, Baden, Switzerland.
Andrea GallinaDepartment of Urology, EOC Ente Ospedaliero Cantonale, Lugano, Switzerland.
Silvia GomezDepartment of Radiation-Oncology, Kantonsspital Aarau, Aarau, Switzerland.
Matthias GuckenbergerDepartment of Radiation-Oncology, University Hospital Zurich, Zurich, Switzerland.
Thomas HerrmannDepartment of Urology, Kantonsspital Frauenfeld, Frauenfeld, Switzerland.
Thomas HermannsZentrum für Urologie Zürich, Zurich, Switzerland.
Ilaria LuccaDepartment of Urology, Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland.
Hubert JohnDepartment of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
Thomas Matthias KesslerDepartment of Neuro-Urology, Balgrist University Hospital, University of Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-1991-5919
Jan KleinDepartment of Urology, Kantonsspital Münsterlingen, Müsterlingen, Switzerland.
Mohamed LaouitiDepartment of Radiation-Oncology, Hôpital Riviera Chablais, Rennaz, Switzerland.
David LaufferDepartment of Radiation-Oncology, University Hospital Geneva, Geneva, Switzerland.
Seth Paul LernerDepartment of Urology, Baylor College of Medicine, Houston, Texas, USA.
Agostino MatteiDepartment of Urology, University Teaching and Research Hospital of the University of Lucerne, Switzerland.
Michael MüntenerDepartment of Urology, Stadtspital Triemli, Zurich, Switzerland.
Daniel NguyenDepartment of Urology, Réseau Hospitalier Neuchâtelois, Neuchâtel, Switzerland.
Philipp NiederbergerDepartment of Oncology, University Teaching and Research Hospital of the University of Lucerne, Lucerne, Switzerland.
Alexandros PapachristofilouDepartment of Radiation-Oncology, University Hospital Basel, Basel, Switzerland.
Lukas PrauseDepartment of Urology, Kantonsspital Aarau, Aarau, Switzerland.
Paul Martin PutoraDepartment of Radiation-Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
Karsten ReinhardtDepartment of Urology, St. Clara Hospital Basel, Basel, Switzerland.
Emanuela SalatiDepartment of Oncology, Hôpital Riviera Chablais, Rennaz, Switzerland.
Philippe SèbeDepartment of Urology, University Hospital Geneva, Geneva, Switzerland.
Mohamed ShelanDepartment of Radiation Oncology, Inselspital Bern, University of Bern, Bern, Switzerland.
Silvan SiggDepartment of Urology, University Teaching and Research Hospital of the University of Lucerne, Switzerland.
Räto Thomas StrebelDepartment of Urology, Kantonsspital Chur, Chur, Switzerland.
Arnoud Jan TempletonDepartment of Oncology, St. Claraspital Basel and Faculty of Medicine, University Basel, Basel, Switzerland.
Ursula VoglDepartment of Oncology, EOC Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Marian Severin WettsteinDepartment of Uro-Oncology, University of Toronto, Toronto, Canada.
Stephen WylerDepartment of Urology, Kantonsspital Aarau, Aarau, Switzerland.
Deborah ZihlerDepartment of Oncology, Kantonsspital Aarau, Aarau, Switzerland.
Thomas ZilliDepartment of Radiation-Oncology, Oncology Institute of Southern Switzerland (IOSI), EOC, Bellinzona, Switzerland.ORCID https://orcid.org/0000-0002-4784-9883
Daniel ZwahlenDepartment of Radiation-Oncology, Kantonsspital Winterthur, Winterthur, Switzerland.
Beat RothDepartment of Urology, Inselspital Bern, Berne, Switzerland.
Christian Daniel FankhauserDepartment of Urology, University Teaching and Research Hospital of the University of Lucerne, Switzerland.ORCID https://orcid.org/0000-0002-4073-5488

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Radical cystectomy or trimodal therapy are treatment options for non-metastatic bladder cancer. However, there is limited evidence guiding post-treatment follow-up regimens, resulting in variations in care. Objective: A Swiss consensus meeting aimed to identify gaps in follow-up strategies and subsequently tailoring follow-up protocols after curative treatment for bladder cancer. Methods: A consensus meeting including participants from urology, oncology, radiation oncology, neuro-urology, international advisors, and patient representatives was held. 19 pre-formulated questions addressing follow-up duration, frequency, and modalities after radical cystectomy or trimodal therapy for bladder cancer were discussed and voted by participants. Results: 42 experts from 22 institutions participated in the meeting. Agreement was reached on several important elements of oncological and functional follow-up like risk-adapted follow-up and regular usage of patient reported outcome measures (PROMs) and 3 novel personalized follow-up schedules were suggested, balancing oncological surveillance, and monitoring functional complications. Conclusion: We agreed on 3 newly developed Swiss follow up schedules for patients with bladder cancer who underwent cystectomy or trimodal therapy with curative intent; these protocols include stage-specific recommendations for type and timing of investigations to detect relapse combined with balanced measures to monitor functional complications such as PROMS and specific clinical examinations. These protocols will be evaluated in a prospective national multicentric cohort study.

Indexed as

bladder cancerfollow upPROMSradical cystectomyrelapsetrimodal therapy

Identifiers

PMID41550985
PMCPMC12811584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.